Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

por Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Publicado 2013

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pa...

por Goldstein, D, Spry, N, Cummins, M M, Brown, C, van Hazel, G A, Carroll, S, Selva-Nayagam, S, Borg, M, Ackland, S P, Wratten, C, Shapiro, J, Porter, I W T, Hruby, G, Horvath, L, Bydder, S, Underhill, C, Harvey, J, Gebski, V J
Publicado 2012

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

por Garlipp, B., Gibbs, P., Van Hazel, G. A., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D. M., Ettorre, G. M., Pardo, F., Donckier, V., Benckert, C., van Gulik, T. M., Goéré, D., Schoen, M., Pratschke, J., Bechstein, W. O., de la Cuesta, A. M., Adeyemi, S., Ricke, J., Seidensticker, M.
Publicado en Br J Surg (2019)